The successful development of adenovirus vectors for vaccines and gene therapy will require a better understanding of the host immune response. Using the ELISPOT assay to measure IFN-g-secreting CD8
Introduction
Adenoviruses have been widely studied as gene-delivery vehicles for vaccines and gene therapy. Successful adenoviral infection and subsequent transgene expression has been demonstrated in a variety of species and target tissues. However, the usefulness of adenoviruses for the delivery of foreign genes is severely limited by the immune response of the host.
1,2 Adenoviral vectors exhibit long-term expression of foreign genes in SCID or other immunocompromised mice, but in most studies with immunologically competent animals transgene expression diminishes over a period of weeks. 3 The rapid disappearance of the desired protein reduces the utility of adenoviral vectors for treatment of chronic conditions and also as vaccines. This point has been further demonstrated by the failure of adenoviral vectors in gene therapy clinical trials.
Both humoral and cell-mediated responses are activated upon the administration of adenoviral vectors. 4 The relative contribution of each depends on the host species, its MHC type, the vector backbone and the transgene. Some researchers have demonstrated that the majority of the host-directed immune response is against the transgene. 5 Highly antigenic proteins such as nonself erythropoietin have been shown to be immunodominant. 6 It is also well established that adenoviral proteins also serve as immunogens. Neutralizing antibodies to adenovirus are well documented in humans 7 and mice. 8 Of greater significance for gene therapy though is the elimination of adenovirus-transduced cells by cell-mediated immunity (CMI). In mice, CD8
þ lymphocytes destroy adenovirusinfected cells in principal target tissues such as the liver, 9 lung 10 and muscle. 5 Whether a single administration of adenovirus is sufficient to generate cytotoxic T lymphocytes, or if the continued 'leaky' expression of virus proteins from E1-deleted vectors is required, is unclear. 11, 12 Several adenoviral proteins have been identified as the principal antigens for CMI. The structural proteins, which comprise the adenovirus capsid, the hexon, penton and fiber, have all been identified as containing MHC class Irestricted epitopes. 13 The hexon protein, the most abundant capsid protein, is a strong stimulator in BALB/c (H-2 d ) mice 14 and also contains a conserved human CD4 þ epitope. 15 In this report, we identify a hexon H-2 d epitope by determining the number of IFN-g-secreting cells with the ELISPOT assay. We also identify the DNA-binding protein, a nonstructural protein that is not packaged in the virion, as containing dominant CD8 þ T-cell epitopes in BALB/c and C57BL/6 (H-2 b ) mice. Owing to the transient transgene expression, most adenovirus-vector gene therapy protocols require multiple administrations. Vectors that are effective with repeated dosing and can evade pre-existing immunity from natural infection will have to be developed. In this repot, we also examine the effect of pre-existing cellular, but not humoral immunity, on adenovirus delivery of a foreign gene in mice.
Results

Identification of adenovirus epitopes
The CD8 þ epitopes of adenovirus type 5 hexon and DNA-binding protein were identified as shown in Figure 1 . The primary sequence of the hexon protein was divided into 24-mer peptides overlapping by 12 amino acids, which were then grouped into pools of 10 peptides and tested in the ELISPOT assay against mice vaccinated with wild-type Ad5 (wtAd5). The DNA-binding protein was divided into 22-mer peptides overlapping by 11 amino acids, which were also grouped into pools of 10 peptides and tested in the ELISPOT assay. Individual peptides from pools that scored positive were then tested in the assay against CD4
þ -and CD8 þ -depleted splenocytes. In BALB/c mice, the hex21 24-mer peptide (amino acids 481-504, LPDKLKYSPSNVKISDNPNTYDYM) and the dbp43 22-mer peptide (amino acids 409-430, LGRQLPKLTPFALSNAEDLDAD) were identified to contain strong CD8 þ epitopes. In C57BL/6 mice, the dbp43 22-mer peptide (amino acids 409-430, LGRQLPKLTPFALSNAEDLDAD) was identified to have the principal CD8 þ epitope. Shorter 9-mer peptides (hex3: KYSPSNVKI, dbp7: LPKLTPFAL, dbp43: FALS-NAEDL) were synthesized and tested for each of the three identified epitopes. Each of these peptides gave signals as high or higher than the longer peptides and was used for all subsequent assays.
Variation of ELISPOT responses in individual mice
ELISPOT assays were typically performed using spleens harvested from several mice and pooled to give an average signal. In order to determine the variability in the ELISPOT assay and the appropriate number of spleens to pool, we conducted ELISPOT assays on individual mice. BALB/c mice were vaccinated with 10 8 viral particles of wtAd5 and 4 weeks later tested in the ELISPOT assay against the hex and dbp peptides. The results of 10 vaccinated mice and three unvaccinated mice tested are shown in Table 1 . In vaccinated mice, the SFC/10 6 ranged from 151 to 570 with an average of 310 and a s.d. of 130 for the hex3 peptide. Against the dbp7 peptide, the number of spot-forming cells per million ranged from 321 to 628 with an average of 456 and a s.d. of 111. Given the range of responses, we found it appropriate to conduct most assays using cells from three pooled spleens.
Dose response of mice to adenovirus vaccination
The magnitude of the T-cell response to adenovirus vaccination was tested over a range of doses. BALB/c and C57BL/6 mice were injected with 10 5 -10 8 viral particles of wtAd5 and half the mice were boosted with the same dose 4 weeks later. The frequency of T cells secreting IFN-g in response to adenovirus peptides was determined in the ELISPOT assay 4 weeks later. As shown in Figure 2a , the BALB/c mice showed an increasing number of IFN-g-secreting cells responding to the dbp and hex peptides with increasing vaccination dose. Boosting added only a marginal increase in the signal at the time point analyzed. The C57BL/6 mice showed a similar pattern, however, the number of IFN-gsecreting cells was lower ( Figure 2b ).
Time course of ELISPOT response
Additionally, we examined how the CD8 þ T-cell response changed over time. Mice were primed with 10 8 particles of Ad5 and 4 weeks later half the animals were boosted with the same dose. From 3 to 12 weeks later, the spleens were harvested and tested in the ELISPOT assay. In BALB/c mice, the ELISPOT response BALB/c mice were vaccinated with 10 8 viral particles of wtAd5 and 4 weeks later tested individually in the ELISPOT assay. The number of SFC/10 6 for 10 vaccinated mice and three unvaccinated mice tested against the hex3 and dbp7 peptides are shown. 
. A second experiment (data not shown) in which the mice were primed (3-12 weeks prior to harvesting the spleens) or primed and boosted 4 weeks later (7-16 weeks prior to harvesting the spleens) also produced the same trend.
Immune response of wild-type versus E1-deleted adenovirus
Most of our studies were performed with wild-type Ad, whereas most of the gene therapy and vaccine studies are conducted using replication defective, E1 À adenovirus vectors. We compared wild-type and E1
À virus in the ELISPOT assay in order to examine the effect of the deletion of the E1 region on CMI. BALB/c and C57BL/6 mice were primed with 10 8 viral particles of wtAd5 or Ad5E1, À boosted 4 weeks later with the same vector, and tested t3 or 6 weeks later in ELISPOT assays. The results are displayed in Table 2 . For both strains, deletion of the E1 region did not significantly change the T-cell responses.
Functional role of T cells in B-cell-deficient mice and pre-existing immunity
We also investigated the functional role of T cells in the antiadeno immune response using adenovirus vectors encoding the secreted alkaline phosphatase (SEAP) gene.
B-cell-deficient mice (Jh strain, H-2 d ) were divided into three groups, which received either no injection, 10 8 or 10 9 viral particles of wtAd5. Sera from these mice were tested for Ad5 neutralization activity, and as expected for B-cell-deficient mice, no neutralization activity was À and boosted 4 weeks later with the same. After 3 or 6 weeks, the cells from three spleens were pooled and tested in the ELISPOT assay against hex or dbp peptides. Data from the BALB/c mice is from 6 weeks postboost and is 3 weeks postboost for C57BL/6 mice.
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detected (data not shown). In addition, some mice were killed and ELISPOT assays were conducted to determine the T-cell response to the hex and dbp peptides. The Jh mice injected with wtAd5 at the 10 9 dose had signals of 210 and 157 IFN-g-secreting cells per million total cells to hex3 and dbp7, respectively. The mice were injected with 10 9 Ad5SEAP 8 weeks after the initial injection with wtAd5 and sera collected at days 2, 5, 8 and 13. The levels of serum SEAP activity at these time points is shown in Figure 4a . Mice that had been previously injected with wtAd5 showed significantly reduced serum SEAP levels at all time points compared to the adenovirus naïve mice. The naive Jh mice had high serum SEAP activity for 8 days until declining to near background level at day 13.
In a second type of experiment to observe the effects of antiadenovirus T-cell immunity, SCID mice that lack B and T cells were injected with 10 7 B-cell-depleted splenocytes from either naïve or wtAd5-primed BALB/ c mice and then challenged with 10 9 viral particles of Ad5SEAP. The serum SEAP activity over the next 34 days is shown in Figure 4b . The SEAP activity in control SCID mice remained unchanged over the 5 weeks examined, while the addition of primed antiadenovirus cells reduced serum SEAP activity to much lower levels over several weeks. The transfer of naïve B-cell-depleted splenocytes also attenuated SEAP activity but at a slower rate than the primed cells. Pre-existing adenovirusspecific T cells accelerate the attenuation of foreign gene expression in the absence of functional B cells. 13 Possible reasons for the differences seen in the response to the DNA-binding protein include the source of antigen, and the nature of the assay. Our source of antigen was peptides, which may be more sensitive than the vaccinia virus encoding the entire DNA-binding protein as used in the previous study. Also, we used the ELISPOT assay that may be more sensitive than the CTL assays performed previously. In people, an immunodominant hexon CD4 þ epitope has been previously defined in HLA-A2 donors, 15 and adenovirus capsid proteins have previously been shown to be targets for cytotoxic T lymphocytes. 16 We further characterized the magnitude and time course of the T-cell response in this model as measured in the ELISPOT assay. A dose-dependent increase in the number of IFN-g cells was seen over a range of 10 5 -10 8 viral particles. Higher doses did not induce a stronger ELISPOT response to the target peptides (data not shown). Also, the data did not show a consistent increase in the number of CD8 þ T cells secreting interferon gamma by a prime/boost regimen over a single vaccination. The failure of repeated injections of adenovirus to boost the signal in the ELISPOT assay is surprising given that we have seen increases in ELISPOT signals to transgenes after repeated vaccinations in similar mouse experiments. The maximum number of IFN-g-secreting cells occurred at the first time point tested (3 weeks), but was still detectable at 12 weeks. The smaller T-cell response seen in the ELISOPT 8 weeks after vaccination is still sufficient to impact subsequent gene expression by a heterologous adenovirus vector. As discussed below, in two different in vivo models using Jh or SCID mice, T-cell immunity after exposure to adenovirus reduces the duration of transgene expression. Additional assays will need to be developed to determine the ratio of memory versus effector T cells observed in the ELISPOT assay over time and their relative effects on subsequent adenovirus exposure.
Discussion
The replication-defective adenovirus vectors used in gene therapy lack the E1 region, which activates transcription of the viral genome after infection. When we compared the T-cell stimulation induced by wildtype Ad5 and a replication-defective first-generation E1-deleted vector, we found similar responses to the hexon 12 or that there is some expression of viral proteins with both wild-type and virus.
11 If the latter case is true, then future vectors will have to be more effective at preventing viral transcription. Vectors with deletions of the other earlytranscribed regions (E2, E3 and E4) and even 'gutless' vectors lacking all viral coding regions have been explored but have not yet been fully evaluated. [17] [18] [19] The role of the E3 region in particular needs to be further defined as it contains immunomodulatory functions. 20 Additional strategies being evaluated to attenuate the host antiadeno response include serotype switching 21, 22 and the coadministration of immunosuppressants. 3, [23] [24] [25] In addition to quantitating the T-cell response to adenovirus epitopes in vitro using the ELISPOT assay, we developed a semiquantitative method to assess the strength of the T-cell response to adenovirus in vivo. The use of Ad5SEAP in Jh mice is a highly effective assay for measuring the effects of adenovirus T-cell responses in vivo. We compared the use of Jh mice to an adoptive transfer experiment in SCID mice similar to one previously reported. 3 Both experiments showed that Tcell immunity to adenovirus reduces subsequent gene expression, but the use of Jh mice is simpler since it does not require in vitro manipulation of the T cells.
In this paper, we have developed quantitative approaches for measuring anti-Ad5 cellular immunity in rodents. These approaches can likewise be extended to studies involving other adenovirus serotypes. Improved quantitation of these immune responses against the viral vector will provide valuable information in assessing the potency of Ad vector approaches for therapeutic and vaccine applications.
Materials and methods
Animals
Female BALB/c, C57BL/6, Jh and SCID mice were obtained from Taconic Laboratories at approximately 4-6 weeks old and given food and water ad lib. For i.m. vaccinations the mice were injected with 50 ml into each rear quadriceps muscle. All experiments were approved by the Institutional Animal Care and Use Committee.
Cell lines and viruses
Cell culture media and reagents were obtained from Invitrogen Corp. unless stated otherwise. WtAd5 was obtained from the ATCC and propagated in Hela cells. The Hela cells were grown in monolayer in minimum essential medium, alpha medium supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 4 mM Lglutamine and 10% (v/v) UV-irradiated fetal bovine serum. AdE1-and Ad5SEAP were propagated in PER.C6 cells 26 grown in monolayer in William's Medium E Modified (Hyclone) supplemented as above. AdE1-and Ad5SEAP are replication-incompetent first generation vectors containing E1 region deletions from nt 342 to 3523 and in the case of Ad5SEAP an E3 deletion from nt 28 133 to 30 818. In Ad5SEAP, the secreted alkaline phosphatase (SEAP) transgene 27 is located in the E1 region in the E1 antiparallel orientation. Transcription of the transgene is driven by the human cytomegalovirus promoter including Intron A 28 and terminated using the bovine growth hormone polyadenylation signal.
Peptides
Peptides were custom synthesized by Research Genetics.
ELISPOT
The ELISPOT assay was performed as previously descibed. 29 Spleens were harvested from BALB/c, Jh or C57BL/6 mice, minced in K media (RPMI medium 1640 supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 4 mM L-glutamine, 55 mM b-mercaptoethanol, 10 mM HEPES and 10% fetal bovine serum) over a mesh insert and the RBCs lysed with AKC lysing buffer. The cells were diluted to 10 7 cells/ml in K media and 100 ml of the cell suspension was added to 100 ml of the appropriate antigen at 2 mg/ml in the well of a 96-well microplate with a nitrocellulose bottom coated with capture antibody (purified rat anti-mouse IFN-g, PharMingen). The plates were incubated for 18-22 h at 371C in 5% CO 2 , washed and 100 ml/well biotinylated rat antimouse IFN-g (PharMingen) was added. The plates were washed again and 100 ml/well streptavidin-AP conjugate (PharMingen) was added. Color was developed by adding 100 ml/well 1-STEP NBT-BCIP (Pierce) for 5-10 min. Spots were counted and the spot-forming cells (SFC) per 10 6 cells were calculated. The nonspecific mitogen concanavalin A was the positive control and produced a solid color in all assays.
Adoptive transfer
Spleens from BALB/c mice were prepared as described above and subsequently depleted of B cells by magnetic separation according to the supplier's instructions using beads coated with an antibody to the mouse B220 antigen (Dynal Biotech). In total, 10 7 B-cell-depleted splenocytes were injected via the tail vein into each SCID mouse. The following day the mice were challenged with 10 9 virus particles of Ad5SEAP.
SEAP assay
Blood was collected from mice via the tail vein and sera collected after centrifugation. The sera was heat-treated for 30 min at 651C to inactivate endogenous alkaline phosphatase activity and the secreted alkaline phosphatase activity measured using a Tropix Phospha-Light luminescence assay (Applied Biosystems). The light output over 5 s was measured on a Dynex MLX luminometer and relative luminescence output converted to ng/ml of SEAP by linear regression of an alkaline phosphatase (Sigma) standard curve.
